- Home
- NRXP vs PASG Comparison
NRXP vs PASG Comparison
Compare NRXP & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- PASG
- Stock Information
- Founded
- NRXP 2015
- PASG 2017
- Country
- NRXP United States
- PASG United States
- Employees
- NRXP N/A
- PASG N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- PASG Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- PASG Health Care
- Exchange
- NRXP Nasdaq
- PASG Nasdaq
- Market Cap
- NRXP 34.7M
- PASG 31.1M
- IPO Year
- NRXP N/A
- PASG 2020
- Fundamental
- Price
- NRXP $2.01
- PASG $0.39
- Analyst Decision
- NRXP Strong Buy
- PASG Strong Buy
- Analyst Count
- NRXP 4
- PASG 3
- Target Price
- NRXP $28.25
- PASG $7.67
- AVG Volume (30 Days)
- NRXP 185.3K
- PASG 163.1K
- Earning Date
- NRXP 05-13-2025
- PASG 05-13-2025
- Dividend Yield
- NRXP N/A
- PASG N/A
- EPS Growth
- NRXP N/A
- PASG N/A
- EPS
- NRXP N/A
- PASG N/A
- Revenue
- NRXP N/A
- PASG N/A
- Revenue This Year
- NRXP N/A
- PASG N/A
- Revenue Next Year
- NRXP N/A
- PASG N/A
- P/E Ratio
- NRXP N/A
- PASG N/A
- Revenue Growth
- NRXP N/A
- PASG N/A
- 52 Week Low
- NRXP $1.10
- PASG $0.33
- 52 Week High
- NRXP $6.01
- PASG $1.64
- Technical
- Relative Strength Index (RSI)
- NRXP 42.26
- PASG 39.40
- Support Level
- NRXP $1.95
- PASG $0.33
- Resistance Level
- NRXP $2.12
- PASG $0.54
- Average True Range (ATR)
- NRXP 0.18
- PASG 0.05
- MACD
- NRXP 0.01
- PASG -0.00
- Stochastic Oscillator
- NRXP 23.08
- PASG 31.13
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About PASG Passage Bio Inc.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.